Clinical trials: Resectable Intrahepatic Cholangiocarcinoma, active
Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence
Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer
This is a prospective, single-arm exploratory study to evaluate the efficacy and safety of chemotherapy combined with Adebrelimab and Apatinib as the perioperative treatment in Patients With Biliary Tract Cancer.
- Trial name
- NCT06280508
- Testing
- Adebrelimab, Apatinib, Gemcitabine, cisplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Intrahepatic Cholangiocarcinoma (Icc)
PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma
The goal of this trial is to determine whether the combination of CISGEM and Rilvegostomig during the perioperative period works to improve outcomes of patient undergoing surgery of high-risk of intrahepatic cholangiocarcinoma
- Trial name
- PEHRICCA (NCT07128290)
- Testing
- CISGEM + Rilvegostomig
- Where
- 9 sites in France
- Volunteers
- 49 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Intrahepatic Cholangiocarcinoma
GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence
Intrahepatic cholangiocarcinoma (ICC) arises from the epithelial cells of bile ducts and occurs proximal to the segmental biliary ducts.
- Trial name
- GOT (NCT05557578)
- Testing
- Tislelizumab combined with GEMOX (GOT) regimen
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
Cholangiocarcinoma Resectable
Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig in Resectable iCCA
Biliary tract cancer is a highly aggressive and heterogeneous group of gastrointestinal cancers that arise from the intra- or extrahepatic bile ducts (CCA), or the gallbladder (GBC)(1-3).
- Trial name
- NEOLANGIO (NCT06569225)
- Testing
- Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Cholangiocarcinoma
A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
To find out if adding pembrolizumab to standard of care chemotherapy drugs (cisplatin and gemcitabine) will improve long-term response of intrahepatic cholangiocarcinoma after surgery, compared to treatment with surgery and…
- Trial name
- NCT05967182
- Testing
- Pembrolizumab, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Resectable Intrahepatic Cholangiocarcinoma
Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, OPTIC Trial
This phase II trial tests the safety and effectiveness of preoperative immunotherapy with durvalumab and chemotherapy with cisplatin and gemcitabine with or without futibatinib targeted therapy in treating patients with…
- Trial name
- NCT07639528
- Testing
- Biospecimen Collection, Cisplatin, Computed Tomography
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Northwestern University
Bile Duct Cancer, Cholangiocarcinoma
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
This trial is designed to study a combination of interventions (chemotherapy, immunotherapy, and radiation) as a potential new treatment for bile duct cancer that cannot be removed with surgery.
- Conditions
- Bile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic
- Trial name
- NCT05655949
- Testing
- Gemcitabine, Cisplatin, Durvalumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Beth Israel Deaconess Medical Center
Cholangiocarcinoma Non-resectable
Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
This is an open-label, single-arm, phase 2 study. The purpose of study is to evaluate the feasibility and safety of hepatic artery infusion chemotherapy combined with lenvatinib and pucotenlimab as conversion therapy for…
- Trial name
- CCGLC-013 (NCT06192797)
- Testing
- HAIC, Lenvatinib plus pucotenlimab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tongji Hospital
Intrahepatic Cholangiocarcinoma
Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
Clinical Study on the efficacy and safety of HAIC（GEMOX）and Lenvatinib combined with Adebrelimab neoadjuvant therapy for resectable Intrahepatic Cholangiocarcinoma with high-risk recurrence factors.
- Trial name
- NCT06208462
- Testing
- Adebrelimab, Lenvatinib, Gemcitabine
- Where
- 3 sites in China
- Volunteers
- 33 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Cholangiocarcinoma, Biliary Tract Cancer (BTC)
Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma
To investigate the efficacy and tolerability of neoadjuvant tislelizumab, gemcitabine, cisplatin and S-1 (TisGCS) in patients with resectable high-risk iCCA.
- Trial name
- TisGCS for BTC (NCT06903273)
- Testing
- Tislelizumab
- Where
- Taiwan
- Volunteers
- 35 people
- Sponsor
- National Cheng-Kung University Hospital
BTC
Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
The primary objective is to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab Injection (QL1706, an Anti-PD-1/CTLA-4 Combined Antibody) combined with GemOX and lenvatinib as conversion therapy for Initially…
- Trial name
- NCT07263360
- Testing
- Iparomlimab and Tuvonralimab Injection combined with GemOX and lenvatinib
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Intrahepatic Cholangiocarcinoma
LIver Transplantation for Non-Resectable Intrahepatic CholAngiocarcinoma (LIRICA)
LIRICA is a prospective non-randomized study aimed at exploring the outcome of liver transplantation in selected patients with unresectable iCCA after a downstaging/disease control protocol with standard of care chemotherapy, in…
- Trial name
- LIRICA (NCT06098547)
- Testing
- Liver transplantation
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Azienda Sanitaria Ospedaliera
Intrahepatic Cholangiocarcinoma
Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC
The goal of this clinical trial is to explore the efficacy and safety of combined infusion chemotherapy with Adebrelimab and Apatinib in the perioperative treatment of resectable intrahepatic cholangiocarcinoma patients.
- Trial name
- NCT06296563
- Testing
- HAIC, Adebrelimab, Apatinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Lei ZHAO
Resectable Intrahepatic Cholangiocarcinoma
Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver Cancer
Treatment of intrahepatic cholangiocarcinoma (ICC) remains difficult. Many patients have unresectable tumors, and survival after resection was only slightly improved with the use of adjuvant capecitabine.
- Trial name
- SIROCHO (NCT05265208)
- Testing
- Capecitabine, Selective Internal Radiotherapy (SIRT), Surgery
- Where
- 7 sites in France
- Volunteers
- 62 people
- Sponsor
- Center Eugene Marquis
Intrahepatic Cholangiocarcinoma, PD1 Antibody
Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
A randomized controlled, multicenter, open, seamless phase II-III clinical trial is designed to target patients with resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors which has extremely low…
- Conditions
- Intrahepatic Cholangiocarcinoma, PD1 Antibody, Lenvatinib, Gemox Chemotherapy
- Trial name
- NCT04669496
- Testing
- Neoadjuvant treatment
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Shanghai Zhongshan Hospital
Intrahepatic Cholangiocarcinoma
Liver Transplantation for Non-Resectable Intrahepatic Cholangiocarcinoma: a Prospective Exploratory Trial (TESLA Trial)
The study will investigate whether liver transplantation provides increased survival, low side effects and good quality of life in patients with bile duct cancer where the tumor cannot be removed by normal surgery.
- Trial name
- NCT04556214
- Testing
- Liver Transplant
- Where
- Norway
- Volunteers
- 15 people
- Sponsor
- Oslo University Hospital
Biliary Tract Cancer (BTC), Biliary Tract Cancer (CCA)
TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World Cohort
Purpose of the Study: Bile duct cancers are rare and aggressive. About 250 new cases are diagnosed each year in Denmark. These cancers are difficult to detect early, so only about 20% of patients can have surgery when diagnosed.
- Conditions
- Biliary Tract Cancer (BTC), Biliary Tract Cancer (CCA), Gall Bladder Cancer, Biliary Tract Cancers (BTC)
- Trial name
- TRACE-BTC (NCT07454486)
- Where
- Denmark
- Volunteers
- 300 people
- Sponsor
- Aarhus University Hospital
Solid Tumor, Adult, Clinical Stage IV Gastric Cancer AJCC v8
Intravital Microscopy in Human Solid Tumors
This study will investigate the tumor-associated vasculature of patients with solid tumors. The investigators will use a technology known as intravital microscopy (IVM) in order to visualize in real-time the vessels associated…
- Conditions
- Solid Tumor, Adult, Clinical Stage IV Gastric Cancer AJCC v8, Malignant Solid Neoplasm, Metastatic Colorectal Carcinoma
- Trial name
- NCT03823144
- Testing
- Diagnostic Microscopy, Fluorescein Sodium Injection
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Mayo Clinic
Intrahepatic Cholangiocarcinoma (Icc)
Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma
This study was a randomized controlled trial to evaluate the efficacy and safety of toripalimab combined with GemCis (gemcitabine and cisplatin) as preoperative neoadjuvant therapy for resectable ICC at high risk of recurrence.
- Trial name
- NCT06721286
- Testing
- Teripalimab, Gemcitabine + Cisplatin, Surgery
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital